Year: 2021

SINGAPORE, Dec. 23, 2021 (GLOBE NEWSWIRE) — Triterras Inc. (NasdaqGM: TRIT, TRITW) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, is providing an update on Nasdaq’s December 10, 2021 determination to delist the Company for failure to file its Form 20-F for the fiscal year ended February 28, 2021. On December 16, 2021, the Company appealed the Staff’s delist determination to the Nasdaq Hearing Panel (the “Panel”) pursuant to Nasdaq rules and requested a stay of the delisting determination and stay of the trading suspension set to expire on January 3, 2022. Following the appeal, on December 20, 2022, the Company provided a further submission to the Panel requesting a stay of the delisting and trading suspension pending the hearing, set for January 20, 2022. Today, the Company is reporting...

HOUSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) — Crown Castle International Corp. (NYSE: CCI) (“Crown Castle”) announced today that Dan Schlanger, Crown Castle’s Executive Vice President and Chief Financial Officer, is scheduled to present on Thursday, January 6, 2022 at 10:00 a.m. Eastern Time at Citi’s 2022 AppsEconomy Conference. Mr. Schlanger’s presentation will be broadcast live over the Internet and is expected to last approximately 45 minutes. The live audio webcast link and presentation for the conference will be available on Crown Castle’s website at http://www.crowncastle.com, where it will also be archived for replay. ABOUT CROWN CASTLE Crown Castle owns, operates and leases more than 40,000 cell towers and approximately 80,000 route miles of fiber supporting small cells and fiber solutions across every major U.S....

Not for distribution to United States Newswire Services or for dissemination in the United States. Vancouver, BC, Dec. 23, 2021 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company” or “Skyharbour”) is pleased to announce it is proceeding on a fully-subscribed, non-brokered private placement financing for total gross proceeds of CAD $500,000 (the “Private Placement”). The majority of this smaller financing is being led by insider participation with an independent director providing the lead order. Skyharbour has allotted and plans to issue 1,000,000 units (the “Units”) at a price of CAD $0.50 per Unit. Each Unit is comprised of one flow-through common share and one-half of one warrant (each whole, a “Warrant”). Each Warrant will entitle the holder to purchase one non-flow through...

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) — Ascendant Digital Acquisition Corp. III (NYSE: ACDI.U) (the “Company”) today announced that, commencing December 31, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the New York Stock Exchange under the symbols “ACDI” and “ACDI WS,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “ACDI.U.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent,...

Validated ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies; the Company’s delivery shuttle enables pharmacology across programs in multiple tissues, including in the brain and muscle, after subcutaneous administration Nominated the development candidate for the myotonic dystrophy type 1 (DM1) program with potential for best-in-class features; initiated IND-enabling studies; and expect to submit an IND filing to the FDA in 4Q CY2022 Established clinical development and CMC teams at new Cambridge, Mass. site; finalized formulation for systemic routes; and scaled-up manufacturing to support GLP toxicology and Phase 1/2 clinical trials for the DM1 program Expect to initiate scale-up and toxicology activities for the development of a systemically...

New York, Dec. 23, 2021 (GLOBE NEWSWIRE) — Brilliant Acquisition Corporation (the “Company”) announced today that it has extended the period of time it will have to consummate its initial business combination by 3 months from the current deadline of December 25, 2021 until March 25, 2022 (the “completion window”) because the Company’s Sponsor, Nisun Investment Holding Limited has timely deposited $460,000 in the Company’s trust account, representing $0.10 per Unit as additional interest on the proceeds in the trust account, pursuant to the terms of the Company’s amended and restated memorandum and articles of association, and the trust agreement entered into between the Company and Continental Stock Transfer & Trust Company. About the Company Brilliant Acquisition Corporation is a blank check company organized for the purpose...

FLORHAM PARK, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech. An inducement grant of 20,000 shares of PDS Biotech’s common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), was awarded as part of Mr. Lalond’s compensation. The award was granted under PDS Biotech’s 2019 Inducement Plan, as amended, in accordance with Nasdaq...

SAMPO PLC                 STOCK EXCHANGE RELEASE         23/12/2021 at 10:30 pm Sampo plc’s share buybacks 23/12/2021 On 23/12/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,860 43.57 AQEU  8,069 43.59 CEUX  1,868 43.61 TQEX  60,201 43.57 XHELTOTAL 78,998 43.57  *rounded to two decimals                 On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is...

JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. (TSXV:CHIP.H), along with a concurrent financing. My Health Logic’s “lab-on-chip” technology platform and patient-centric digital point-of-care device, MATLOC 1, further strengthens Marizyme’s life science technology product pipeline. Marizyme is actively seeking FDA approval for both MATLOC1 and a second product, DuraGraft. My Health Logic’s MATLOC and Lab-on-Chip Technology Platform The excitement over microfluidics, also known as lab-on-a-chip technology, lies in its potential for producing revolutionary, timely, accessible, and practical point-of-care devices; devices that...